The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CTXR | -64.26% | -96.25% | -48.15% | -100% |
| S&P | +15.66% | +86.6% | +13.29% | +255% |
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$62.04K | -15.6% |
| Market Cap | $21.10M | -76.7% |
| Market Cap / Employee | $917.18K | 0.0% |
| Employees | 23 | 0.0% |
| Net Income | -$8,743.65K | 21.1% |
| EBITDA | -$8,375.27K | 23.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.25M | 30.8% |
| Inventory | 22.3 | 169.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $724.93K | 3300.5% |
| Short Term Debt | $1.09M | 350.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -30.21% | 5.3% |
| Return On Invested Capital | -38.41% | 0.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$11,880.79K | -100.9% |
| Operating Free Cash Flow | -$11,880.79K | -100.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.41 | 0.18 | 0.23 | 0.28 | -78.68% |
| Price to Tangible Book Value | -0.90 | -0.31 | -0.34 | -0.48 | -100.36% |
| Enterprise Value to EBITDA | -3.26 | -1.48 | -1.81 | -3.58 | -57.14% |
| Return on Equity | -52.9% | -60.1% | -53.4% | -54.4% | 11.82% |
| Total Debt | $204.57K | $931.80K | $1.88M | $1.81M | 589.81% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
